Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | LMWH does not prevent VTE in adults with newly diagnosed ALL: side study of the HOVON-100 trial

Mandy Lauw • 14 Jun 2024
EHA 2024
Acute Lymphoblastic Leukemia Leukemia Heparin
HOVON-100

Venous thromboembolism (VTE) is a common complication that can occur in patients with acute lymphoblastic leukemia (ALL). In this presentation, Mandy Lauw, MD, PhD, Erasmus Medical Center, Rotterdam, the Netherlands, shares insights into a study which evaluated the efficacy of thromboprophylaxis using low molecular weight heparin (LMWH) in adults aged 18-70 with newly diagnosed ALL. This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals